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We describe the first case of a FLT-3 mutated AML in a healthy donor, 3 years after recombinant
human granulocyte colony stimulating factor (rhG-CSF)-mobilized peripheral blood stem cell
(PBSC) harvest. The patient had a myeloablative (MA) matched unrelated donor (MUD) stem cell
transplant (SCT) for refractory AML. However, he experienced a secondary graft failure. He had
a second non myeloablative (NMA) on day +75 from a second MUD. He achieved a complete neu-
trophil and platelet engraftment. After 4 years of follow up, he is alive in complete remission
with full second donor chimerism.
 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Over the last decade, the main source of stem cell donation
has changed from bone marrow to peripheral blood stemcells (PBSCs). In 2012, 10,989 unrelated donors donated
recombinant human granulocyte colony-stimulating factor
(rhG-CSF)-mobilized PBSCs [1]. This number has increased
from 9248 donors in 2010, reflecting the growing worldwide
utilization of this stem cell collection method. However,
concerns emerged about the long-term tumorigenic effects
of rhG-CSF on the donors coupled with the ethical consider-
ation of administering a drug to a healthy individual.
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A 30-year-old male hematopoietic stem cell donor under-
went peripheral stem cell mobilization with filgrastim, an
rhG-CSF. He presented with fatigue and exertional dyspnea
approximately 3 years after stem cell donation. A complete
blood count revealed the following measurements: white
blood cell, 9.4  101/L; platelet count, 140  109/L; hemo-
globin, 6.5 g/dL; and 54% circulating blasts. The bone mar-
row aspirate was hypercellular and largely replaced by
myeloid blasts. Cytogenetic and molecular testing revealed
trisomy 9 and internal tandem duplication (ITD) mutations
of the juxtamembrane domain coding sequence of the
Fms-like tyrosine kinase 3 gene (FLT3-ITD) mutation. Subse-
quent bone marrow testing for his recipient did not detect
these abnormalities.
The patient was enrolled in a Phase III placebo-controlled
trial of induction chemotherapy with cytarabine, daunoru-
bicin, and midostaurin (an oral FLT3 receptor inhibitor).
He received two induction courses. A follow-up bone mar-
row biopsy showed 7% blasts by morphology and 10% myeloid
blasts by immunohistochemistry with persistent trisomy 9
and FLT3-ITD mutation. Therefore, he underwent a
myeloablative matched unrelated donor (MUD) allogeneic
stem cell transplant (allo SCT) with busulfan and cyclophos-
phamide conditioning. For graft-versus-host disease (GvHD)
prophylaxis, he received antithymocyte globulin, tacroli-
mus, and methotrexate. The transplant course was compli-
cated by prolonged pancytopenia. Neutrophils engrafted on
Day +30 and peaked at 4.3  109/L on Day +46. The patient
did not achieve platelet engraftment and remained platelet
and red blood cell transfusion dependent. On Day +50, he
presented with absolute neutrophil count of 0.3  109/L.
A bone marrow biopsy revealed markedly hypocellular mar-
row with 2+ reticulin fibrosis. The aspirate contained very
few cells that were mostly small lymphocytes. Chimerism
testing for CD3 and CD33 were 93% and 100% recipient cells,
respectively. Results of viral studies for parvovirus B19,
cytomegalovirus, Epstein–Barr virus, adenovirus, and
human herpesvirus 6 were negative. The patient underwent
a second nonmyeloablative allo SCT MUD SCT from a differ-
ent donor on Day+ 75. The conditioning regimen was flu-
darabine and total-body irradiation and GvHD prophylaxis
consisted of tacrolimus and mycophenolate mofetil. He
achieved and sustained neutrophil and platelet engraftment
starting on Day+ 10. Chimerism studies on Day+ 60 con-
firmed 100% donor engraftment in both lymphoid and mye-
loid cell lines. At the 4-year follow-up, the patient and his
recipient (6-year follow-up) are both alive and in remission.
Discussion and conclusion
G-CSF is an essential regulator of neutrophil production
under basal conditions of hematopoiesis as well as during
reactive granulopoiesis in response to bacterial infections.
It exerts this role by inducing proliferation and survival of
myeloid progenitor cells, followed by cell-cycle arrest and
neutrophilic differentiation.
A few studies addressed the potential impact of rhG-CSF
on chromosomal integrity. Nagler et al. [2] concluded that,in rhG-CSF-mobilized donors, lymphocytes developed tran-
sient loss of synchrony in allelic replication as well as more
prolonged aneuploidy of chromosome 17 (up to 9 months
following rhG-CSF exposure). This study was criticized
because of the inappropriateness of controls, the failure
to separate malignant cells in the lymphocyte samples from
the leukemia patients, and the nonconventional statistical
methods used to analyze the data [3].
In another study, tetraploid myeloid cells constituted up
to 0.6% of differentiated myeloid cells in the peripheral
blood of donors who received rhG-CSF [4]. Critics ques-
tioned the interpretation of these results given the small
sample size (10 patients), possible selection bias, and lack
of data from untreated controls [3]. Thus, these two studies
do not provide conclusive evidence regarding any impact
rhG-CSF may have on chromosomal integrity.
Contrary to these findings, a study by Olnes et al. [5]
from the National Institutes of Health did not detect aneu-
ploidy in chromosomes 7 and 8 in 35 G-CSF-mobilized
healthy donors and in 38 G-CSF/dex-treated granulocyte
donors.
The adverse effects of rhG-CSF on stem cell donors were
evaluated in two independent large studies [6,7]. The
National Marrow Donor Program (NMDP) prospectively eval-
uated a cohort of 2408 unrelated PBSC donors between 1999
and 2004. After a median follow-up of 49 months, no cases
of acute myeloid leukemia (AML) or myelodysplastic syn-
drome (MDS) were reported. The incidence of cancer in this
cohort was comparable with the reported incidence accord-
ing to the Surveillance, Epidemiology, and End Results data-
base [6].
A German registry-based study reported on 3928 consecu-
tive unrelated stem cell donors after a follow-up of 5 years.
Malignancies occurred in 12 donors (0.3%) including only
one case of AML, one case of chronic lymphocytic leukemia,
and two cases of Hodgkin’s disease. Only the incidence of
Hodgkin’s lymphoma differed significantly from an age-
adjusted population (incidence in Germany 2.3–
2.4/100,000/year; 95% confidence interval 1.06–31.98) [7].
Two retrospective analyses of large cohorts of donors by
the NMDP and the German Marrow Donor Registry showed no
increased incidences of leukemia and lymphoma compared
with age-adjusted incidences of the general population
[8,9].
Given the low incidence of secondary AML, longer follow-
up of donors might be needed to see if such association
exists [10].
FLT3-ITD mutations have been identified in 17–34% of
AML and 5% of MDS patients. This subset of AML patients is
typically characterized by de novo presentation, leukocyto-
sis, decreased response to induction chemotherapy, high
relapse rate, and overall poor prognosis [11].
We herein reported the case of FLT3-ITD-positive AML
3 years after rhG-CSF mobilization of PBSC in an unrelated
donor. So far, evidence from literature and donor registries
follow-up studies does not support any association between
G-CSF administration to healthy donors and the occurrence
of G-CSF-induced malignant transformation. However, given
the theoretical risk of malignant transformation in the set-
ting of growth factors use, vigilance and long-term follow-
up of donor complications is recommended.
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